Physician profile
Gilbert Melson
NPI 1235512591
$1,624.96
in general payments reported to CMS, 2019-2025
19 companies · $509 in 2025
The $509 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $270 · 2022: $521 · 2023: $175 · 2024: $150 · 2025: $509.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $834.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $834.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $461.21 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $281.89 | 2022-2025 | |
| Lilly USA, LLC | $226.81 | 2022-2025 | Zepbound |
| Janssen Pharmaceuticals, INC | $111.05 | 2021 | |
| Glaxosmithkline, LLC. | $91.48 | 2022-2025 | Trelegy Ellipta |
| Horizon Therapeutics Plc | $78.24 | 2022 | |
| Novo Nordisk INC | $60.77 | 2025 | Ozempic |
| Irhythm Technologies, INC. | $52.59 | 2023-2024 | Zio Xt Patch, Zio Monitor |
| Amgen INC. | $49.02 | 2022-2025 | Otezla, Repatha, Otezla |
| Vanda Pharmaceuticals INC. | $36.73 | 2025 | Fanapt |
| Pfizer INC. | $29.95 | 2022-2023 | |
| Xeris Pharmaceuticals, INC. | $23.98 | 2024 | Gvoke Hypopen |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $23.85 | 2023 | |
| Lundbeck LLC | $22.43 | 2025 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.25 | 2024 | Xifaxan |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $15.76 | 2025 | Rexulti |
| Exact Sciences Corporation | $15.08 | 2025 | Cologuard Collection Kit |
| Idorsia Pharmaceuticals US INC | $14.16 | 2023 | Quviviq |
| Medtronic, INC. | $13.71 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gilbert Melson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.